Is Australia the future for successful first-in-human clinical studies?
The number of biotech-sponsored clinical trials in Australia has grown by more than +10% on average each year between 2017…
accelerating clinical trials
-
-
How biotechs can tap APAC for excellence in oncology trials
Asia-Pacific biotech specialist CRO Novotech has released a new webinar about the advantages of conducting oncology clinical trials in the…
-
Why Asia-Pacific attracts 60% of all ongoing and planned hepatology trials globally
There are more than 1,300 clinical trials in hepatology, either ongoing or planned, in Asia-Pacific. This represents about 60% of…
-
Biotechs testing for COVID-19 in Asia-Pacific benefit from new fast-track review processes
Many countries in the Asia-Pacific region are now fast-tracking their COVID-19 clients’ clinical trials with expedited review processes for treatment…
-
Data shows majority of Australian sites are open for clinical trial activity
Novotech, the Asia-Pacific CRO, has published data detailing the current status of clinical trials in the Asia-Pacific region during the…
-
Managing the Covid-19 outbreak: Lessons learnt from South Korea
Due to its geographic proximity with China, South Korea was one of the first locations hit with the Covid-19 viral…
-
Clinical trials data report for Asia-Pacific: Frost & Sullivan collaborates with Novotech
Business consulting firm Frost & Sullivan and Asia-Pacific CRO specialist Novotech published a report summarising the main trends and developments…
-
Novotech case study: Global reach through CRO partnership for a phase 2 oncology trial
The alliance of regional specialists can provide the best of all worlds: global coverage, regional specialisation and mid-sized CRO flexibility.…
-
Case studies in accelerating clinical trials in oncology
Clinical development in oncology and immunotherapies has accelerated dramatically over the past few years. As of December 2019, over 6,000…
-
Regulatory requirements for clinical trials: A comparison of Australia and the US
The regulatory environment in Australia and New Zealand offers a significant strategic opportunity for international biotech companies wanting a fast…
